Objectives: to study the relationship between serum level of ghrelin and cachexia in patients with COPD. Background: Chronic obstructive pulmonary disease is a major cause of chronic morbidity and mortality throughout the world. COPD involves several systemic features. The link between ghrelin, cachexia and COPD needs to be clarified.
Introduction
Chronic obstructive pulmonary disease (COPD) is a common preventable and treatable disease, characterized by persistent air flow limitation which is usually progressive and associated with enhanced chronic inflammatory response in the airway and the lung to noxious particles and gases (1). Cachexia, which is a catabolic state characterized by weight loss and muscle wasting, occurs frequently in patients with COPD and is also an independent risk factor for death in these patients (2). In addition to excessive energy expenditure on exertive breath and the inflammatory response, patients with COPD, especially those with acute exacerbations, usually have a worse appetite and ingest less food (3, 4).
Appetite is regulated by a variety of peptides; one of the most important peptides studied in cases of COPD is ghrelin.
Ghrelin is a 28-amino acid peptide mainly synthesized in X/A cells of the oxyntic glands in the mucosa layer of the gastric fundus. Ghrelin is present in human plasma in two forms: an inactive form known as deacylated ghrelin, and an active form, the acylated ghrelin synthesized under the action of ghrelin O-acyltransferase enzyme (GOAT) (5, 6). The acylation modification provides large hydrophobic groups, which are essential for activation of the growth hormone secretagogue receptor (7).
Acylated ghrelin is a potent stimulator of gastric secretion and motility (8). The circulating levels of ghrelin are elevated during fasting and before meals and decline postprandially, which implies that ghrelin plays a significant role in initiating food intake (9, 10). Ghrelin is considered an orexigenic signal (gut-brain) , that increases appetite and stimulates food intake by activating hypothalamic neuropeptide Y/agouti-related peptide-containing neurons, which also express GHS-R type 1a (GH secretagogue receptor 1a), via the modulation of fatty acid metabolism (11, 12) .
Given that ghrelin has GH-releasing activity, ghrelin may have beneficial effects in cachexia associated with COPD patients through a GHdependent mechanism. As GH is an anabolic hormone, protein stores are spared at the expense of fat during conditions of caloric restriction (13).
Meanwhile, as a GH-independent mechanism, ghrelin induces a positive energy balance by decreasing fat utilization (14), stimulating food intake and adipogenesis and lipogenesis in murine and human adipocytes (15), increasing cardiac output in healthy humans (16), and inhibiting sympathetic nerve activity (17).
Due to the above actions, ghrelin exhibits anticachectic actions and used in the treatment of cachexia caused by a variety of diseases including chronic obstructive pulmonary disease. Nagaya et al., studied the effect of exogenous ghre lin administration in cachectic patients with COPD and they found that repeated administration of ghrelin stimulated feeding, increased body weight and lean body mass and increased peripheral and respiratory muscle strength (18).
All these data suggest that we have to clarify the role of ghrelin in cases of cachexia associated with COPD patients. So, the aim of this work was to study the relationship between serum level of ghrelin and cachexia in patients with COPD.
Subjects and methods
The present study was conducted on 60 diagnosed patients with COPD admitted to Chest Department, Menoufia University Hospitals and 30 age matching healthy persons were used as a control group.
After having a written consent, each patient underwent:
1. Medical history taking.
2. Physical examination (general and local).
3. Electrolytes and lipid profile. There was highly significant difference between serum levels of ghrelin in correlation to level of obstruction as the highest level was detected in severe obstruction and decreased as obstruction get
better Tables V and VI.
Discussion
This work was carried out on 60 diagnosed patients with COPD. They were subdivided into three equal subgroups according to body mass index: Normal weight COPD patients with BMI 18.5-24.9, overweight COPD patients with BMI over 25 and underweight COPD patients with BMI less than 18.5. 30 non COPD, age matching healthy persons were studied as a control group.
Serum ghrelin was measured for all subjects.
In the present study despite there is no significant difference between both groups as regard cigarette smoking and this may be due to group selection, still smoking one of the most important risk factors for development of COPD as it produces a large amount of reactive oxygen species (ROS) that induces an oxidant burden in smokers (21-25) and disrupts the oxidant-antioxidant mechanisms that On the other hand reduced ghrelin secretion in obese patients was found to be an adaptive mechanism to a long-term positive energy balance.
Although circulating plasma ghrelin levels are low in obese people, a lack of postprandial ghrelin suppression was observed, which could contribute to increased food intake in these people (45).
Conclusions
From the present study we can conclude that serum level of ghrelin is increased in COPD patients, it was higher in the underweight patients than in the normal weight patients with COPD and have significant relation to the severity of COPD. So serum ghrelin level may be a useful indicator for malnutrition in COPD patients and may be involved in the pathogenesis of COPD by affecting the body energy metabolism. 
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